How do you choose between liso-cel and axi-cel in patients with early relapse DLBCL for whom you are recommending CAR T-cell therapy?  

Axi-cel and liso-cel are anti-CD19 chimeric antigen receptor (CAR) T-cell products approved for primary refractory or early relapsed (<1 year from initial chemoimmunotherapy) diffuse large B-cell lymphoma (DLBCL). Both products exhibit excellent efficacy (overall response rates >80%) and are p...

Lisocabtagene maraleucel and axicabtagene ciloleucel are both FDA-approved in the 2nd-line setting for patients with DLBCL that is primary refractory or relapsing within 12 months of completing frontline therapy. They were both shown to have a significant event-free survival benefit over salvage che...